ZA961647B - Human t-cell line infected with hiv-2 which secretes functionally intact hiv-2 gp 160 - Google Patents
Human t-cell line infected with hiv-2 which secretes functionally intact hiv-2 gp 160Info
- Publication number
- ZA961647B ZA961647B ZA961647A ZA961647A ZA961647B ZA 961647 B ZA961647 B ZA 961647B ZA 961647 A ZA961647 A ZA 961647A ZA 961647 A ZA961647 A ZA 961647A ZA 961647 B ZA961647 B ZA 961647B
- Authority
- ZA
- South Africa
- Prior art keywords
- hiv
- cell line
- protein
- humans
- purified
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 abstract 6
- 241000713340 Human immunodeficiency virus 2 Species 0.000 abstract 5
- 239000003636 conditioned culture medium Substances 0.000 abstract 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 abstract 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 229940121357 antivirals Drugs 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000012894 fetal calf serum Substances 0.000 abstract 1
- 239000002609 medium Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 238000003156 radioimmunoprecipitation Methods 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 239000012679 serum free medium Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 210000002845 virion Anatomy 0.000 abstract 1
- 238000001262 western blot Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
- G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/402,481 US5736317A (en) | 1995-03-07 | 1995-03-07 | Human T-cell line infected with HIV-2 which secretes a protein corresponding to native HIV-2 gp160 in an extracellular medium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA961647B true ZA961647B (en) | 1996-09-05 |
Family
ID=23592081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA961647A ZA961647B (en) | 1995-03-07 | 1996-02-29 | Human t-cell line infected with hiv-2 which secretes functionally intact hiv-2 gp 160 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US5736317A (xx) |
| EP (1) | EP0731165B8 (xx) |
| JP (1) | JPH09246A (xx) |
| KR (1) | KR960034405A (xx) |
| AT (1) | ATE297984T1 (xx) |
| AU (1) | AU710064B2 (xx) |
| CA (1) | CA2171144A1 (xx) |
| DE (1) | DE69634843T2 (xx) |
| ES (1) | ES2240986T3 (xx) |
| ZA (1) | ZA961647B (xx) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197496B1 (en) | 1988-06-09 | 2001-03-06 | Institut Pasteur | Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins gp300, p200, and p90/80 |
| US5208321A (en) | 1988-06-09 | 1993-05-04 | Institut Pasteur | HIV-2 transmembrane glycoprotein homodimer (GP 80) |
| US6271077B1 (en) | 1995-03-27 | 2001-08-07 | Fujitsu Limited | Thin film deposition method, capacitor device and method for fabricating the same, and semiconductor device and method for fabricating the same |
| US6410692B2 (en) * | 1998-02-02 | 2002-06-25 | Novadx, Inc. | Removal of abundant interfering proteins from a liquid sample using a collapsible affinity matrix |
| WO2001097858A2 (en) | 2000-06-20 | 2001-12-27 | Idec Pharmaceuticals Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| BR0208944A (pt) | 2001-04-16 | 2006-10-10 | Wyeth Corp | quadros de leitura aberta de streptococus pneumoniae codificando os antìgenos de polipeptìdeos e seus usos |
| CN1500806B (zh) * | 2002-11-14 | 2010-05-05 | 上海科华生物工程股份有限公司 | 一种HIV－1ɡp160膜蛋白及其制备方法和应用 |
| WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| US20080026448A1 (en) * | 2006-02-15 | 2008-01-31 | Lydersen Bjorn K | Production of HIV |
| ES2625406T3 (es) | 2010-03-25 | 2017-07-19 | Oregon Health & Science University | Glicoproteínas de CMV y vectores recombinantes |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3712334C2 (de) * | 1987-04-11 | 1995-04-27 | Paul Ehrlich Inst Bundesamt Fu | Verfahren zum Züchten von HIV-2-Viren, dazu geeignete Zellkulturen sowie diagnostische Mittel zum Nachweis von HIV-2-Viren und Verfahren zu ihrer Herstellung |
| WO1989006276A2 (en) * | 1988-01-08 | 1989-07-13 | Dpz Deutsches Primatenzentrum Gesellschaft Mbh | Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions |
| US5122468A (en) * | 1988-08-16 | 1992-06-16 | Akzo N.V. | Hut-78 cell lines infected with HTLV-III which secrete gp160 |
| US5116740A (en) * | 1988-08-16 | 1992-05-26 | Akzo N.V. | Method for producing native hiv gp160 |
-
1995
- 1995-03-07 US US08/402,481 patent/US5736317A/en not_active Expired - Lifetime
-
1996
- 1996-02-29 ZA ZA961647A patent/ZA961647B/xx unknown
- 1996-03-04 EP EP96200578A patent/EP0731165B8/en not_active Expired - Lifetime
- 1996-03-04 DE DE69634843T patent/DE69634843T2/de not_active Expired - Lifetime
- 1996-03-04 ES ES96200578T patent/ES2240986T3/es not_active Expired - Lifetime
- 1996-03-04 AT AT96200578T patent/ATE297984T1/de not_active IP Right Cessation
- 1996-03-06 JP JP8048902A patent/JPH09246A/ja active Pending
- 1996-03-06 KR KR1019960005761A patent/KR960034405A/ko not_active Application Discontinuation
- 1996-03-06 CA CA002171144A patent/CA2171144A1/en not_active Abandoned
- 1996-03-06 AU AU47929/96A patent/AU710064B2/en not_active Expired
- 1996-07-03 US US08/676,865 patent/US5766844A/en not_active Expired - Lifetime
-
1998
- 1998-04-14 US US09/059,804 patent/US5876732A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US5736317A (en) | 1998-04-07 |
| DE69634843D1 (de) | 2005-07-21 |
| ATE297984T1 (de) | 2005-07-15 |
| US5766844A (en) | 1998-06-16 |
| EP0731165B8 (en) | 2005-08-10 |
| EP0731165A2 (en) | 1996-09-11 |
| CA2171144A1 (en) | 1996-09-08 |
| AU710064B2 (en) | 1999-09-09 |
| JPH09246A (ja) | 1997-01-07 |
| DE69634843T2 (de) | 2006-05-04 |
| ES2240986T3 (es) | 2005-10-16 |
| EP0731165A3 (en) | 1999-09-08 |
| EP0731165B1 (en) | 2005-06-15 |
| AU4792996A (en) | 1996-09-19 |
| US5876732A (en) | 1999-03-02 |
| KR960034405A (ko) | 1996-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0731165B8 (en) | Human T-cell line infected with HIV-2 which secretes functionally intact HIV-2 GP160 | |
| Montagnier et al. | Identification and antigenicity of the major envelope glycoprotein of of lymphadenopathy-associated virus | |
| US5030718A (en) | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes | |
| AU632475B2 (en) | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals | |
| US4812556A (en) | Synthetic peptide antigen for the detection of HIV-2 infection | |
| US5550052A (en) | Hybrid cell line formed between T4 lymphocytes and tumoral lymphoid type cells | |
| EP0891982A3 (en) | HIV peptides | |
| EP0327801A1 (en) | HIV-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions | |
| US5364933A (en) | Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2) | |
| DE69131513D1 (de) | Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon | |
| US6531574B1 (en) | T-lymphotrophic virus | |
| Tozawa et al. | Species‐dependent antigenicity of the 34‐kDa glycoprotein found on the membrane of various primate lymphocytes transformed by human t‐cell leukemia virus type‐I (HTLV‐I) and simian T‐cell leukemia virus (STLV‐I) | |
| US5116740A (en) | Method for producing native hiv gp160 | |
| US6165710A (en) | Method for immobilizing viral glycoproteins for use in solid-phase immunoassays | |
| Keller | The stability of neutralization of poliovirus by native antibody and enzymatically derived fragments | |
| US5122468A (en) | Hut-78 cell lines infected with HTLV-III which secrete gp160 | |
| EP0329761B1 (en) | Hiv-1-related polypeptides, diagnostic systems and assay methods | |
| US5562905A (en) | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals | |
| EP0345559A2 (en) | HIV-2 variants | |
| US6541609B2 (en) | HIV-2 peptides | |
| Vornhagen et al. | Recombinant antigens in viral diagnosis | |
| IE892612L (en) | METHOD FOR PRODUCING NATIVE HIV gp160 |